# EDGAR Filing Document

**Accession Number:** 0001724979
**File Stem:** 0001104659-23-031305
**Filing Date:** 2023-3
**Character Count:** 4218
**Document Hash:** 63dd14a7097b00dbc50c9888a4a9662e
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-23-031305.hdr.sgml**: 20230310

**ACCESSION NUMBER**: 0001104659-23-031305

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 12

**CONFORMED PERIOD OF REPORT**: 20230310

**ITEM INFORMATION**: Regulation FD Disclosure

**FILED AS OF DATE**: 20230310

**DATE AS OF CHANGE**: 20230310

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Rain Oncology Inc.
- **CENTRAL INDEX KEY:** 0001724979
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 821130967
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-40356
- **FILM NUMBER:** 23724877

**BUSINESS ADDRESS:**
- **STREET 1:** 8000 JARVIS AVENUE
- **STREET 2:** SUITE 204
- **CITY:** NEWARK
- **STATE:** CA
- **ZIP:** 94560
- **BUSINESS PHONE:** (510) 953-5559

**MAIL ADDRESS:**
- **STREET 1:** 8000 JARVIS AVENUE
- **STREET 2:** SUITE 204
- **CITY:** NEWARK
- **STATE:** CA
- **ZIP:** 94560

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Rain Therapeutics Inc.
- **DATE OF NAME CHANGE:** 20171211

?xml version="1.0" encoding="utf-8"?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**PURSUANT TO SECTION 13 OR 15(d)**

**OF THE SECURITIES EXCHANGE ACT OF 1934**

**Date of Report (Date of earliest event reported): March 10, 2023**

**Rain Oncology Inc.**

**(Exact **N**ame of **R**egistrant as **S**pecified in its **C**harter)**

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-40356** | **82-1130967** |
| **(State or **O**ther **J**urisdiction**<br> **of **I**ncorporation)** | **(Commission**<br> **File Number)** | **(IRS Employer**<br> **Identification No.)** |

---

**8000 Jarvis Avenue, Suite 204**

**Newark, CA 94560**

**(Address of **P**rincipal **E**xecutive **O**ffices)**

**(510) 953-5559**

**(Registrant's telephone number, including area code)**

**N/A**

**(Former Name or Former Address, if Changed Since Last Report)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 210.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading<br> Symbol(s)** | **Name of each exchange<br> on which registered** |
| **Common Stock, par value $0.001 per share** | **RAIN** | **The Nasdaq Global Select Market** |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company ⌧

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ◻

---

| | |
|:---|:---|
| **Item 7.01** | **Regulation FD Disclosure.** |

---

Rain Oncology Inc. (the "Company") is aware of media reports indicating California's banking regulator has taken possession of Silicon Valley Bank ("SVB"). The Company has no exposure to any liquidity concern at SVB.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
| Dated: March 10, 2023 | **Rain Oncology Inc.** | **Rain Oncology Inc.** |
|  | By: | /s/ Avanish Vellanki |
|  |  | Avanish Vellanki |
|  |  | *Chairman and Chief Executive Officer* |

---